Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free

Parabilis Medicines, Inc. is rated a speculative Buy due to its innovative peptide platform and strong rare-disease oncology pipeline. Lead asset zolucatetide (zolu) shows robust early efficacy in desmoid tumors and craniopharyngioma, with favorable safety and FDA Orphan/Fast Track designations. PBLS benefits from a $125M upfront/Regeneron partnership, $1.1B cash, and a projected cash runway into 2030, minimizing near-term dilution risk.

Seeking Alpha • Oct 20, 2026

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026

Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors Company to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12 p.m.

GlobeNewsWire • Oct 19, 2026

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors

GlobeNewsWire • Oct 14, 2026

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D.

GlobeNewsWire • Sep 1, 2026

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.

GlobeNewsWire • Aug 25, 2026

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus competitors.

Seeking Alpha • Aug 14, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors

GlobeNewsWire • Aug 13, 2026

Primary Markets Group June 2026 U.S. IPO Update

The U.S. IPO market shattered records in June 2026, propelled by the ‘out of this world' debut of Space Exploration Technologies Corp. The month saw 19 IPOs raising a staggering $97.9 billion, which was a dramatic increase from the $13.1 billion raised across 12 deals in May and the $4.2 billion across 10 IPOs in June 2025. Looking at pricing performance, the best first-day performance came from healthcare firm Parabilis Medicines, Inc., which increased 58.0% after pricing its offering above its initial filing range.

Seeking Alpha • Jul 17, 2026

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Jul 6, 2026